Board of Trustees
The Sabin Vaccine Institute Board of Trustees oversees the activities of the organization and our various programs. We are grateful for the activism and generosity of our Board of Trustees, composed of international leaders in business, civil service, academia and philanthropy.
Axel Hoos, M.D., Ph.D.
Michael W. Marine, Ambassador (Ret.)
Regina Rabinovich, M.D., M.P.H.
Philip K. Russell, M.D.
Peter L. Thoren
H. R. Shepherd, D.Sc.
Executive Committee Chair
Dr. Axel Hoos is senior vice president, R&D governance chair, and Therapeutic Area (TA) head for Oncology at GlaxoSmithKline Pharmaceuticals (GSK). He is responsible for discovery and development in Oncology with focus on immuno-oncology, epigenetics, cell therapies and genetic medicine. As R&D governance chair, he oversees technical and funding review committees.
He returned GSK to Oncology after the divestment of its marketed medicines to Novartis in 2015 and is responsible for GSK's Oncology portfolio focusing on innovative medicines to deliver transformational benefit to patients. Recent portfolio expansion included the acquisition of Tesaro, a co-development partnership with Merck-Serono, and the in-licensing of the first cell therapy active in solid tumors from Adaptimmune.
Dr. Hoos also serves as chairman of the Board of Trustees of the Sabin Vaccine Institute, director on the Board of Imugene, a biotech company, co-director of the Cancer Immunotherapy Consortium and member of the Scientific Advisory Board of the Cancer Research Institute.
His efforts focus on novel therapies for life-threatening diseases, scientific and technical innovation, and business and scientific collaboration. Through his leadership, a paradigm for the development of cancer immunotherapies has been defined, which helped launch the field of Immuno-Oncology (Nat. Rev. Drug Discovery 2016, 15(4):, 235-47)
Previously, Dr. Hoos was the global medical lead in Immunology/Oncology at Bristol-Myers Squibb (BMS) where he developed Yervoy (Ipilimumab), the first life-extending therapy and the first checkpoint inhibitor drug in Immuno-Oncology. The discovery of Ipilimumab’s scientific mechanism was honored with the Nobel Prize for Physiology or Medicine to Dr. James Allison in 2018. Before BMS, Dr. Hoos was senior director of Clinical Development at Agenus Bio (previously Antigenics), a biotech company.
Dr. Hoos holds a medical degree from Ruprecht-Karls-University and a doctoral degree in molecular oncology from the German Cancer Research Center both in Heidelberg, Germany. He trained in surgery at the Technical University in Munich and further in surgery, molecular pathology and tumor immunology at Memorial Sloan-Kettering Cancer Center in New York City. He is an alumnus of the Program for Leadership Development at Harvard Business School.
Chief Executive Officer
Amy Finan was appointed as the chief executive officer of the Sabin Vaccine Institute on April 18, 2016. In her time as CEO, Amy has led the development and implementation of a strategic plan focusing Sabin on a mission to make vaccines more accessible, enable innovation and expand immunization across the globe.
Prior to joining Sabin, Amy served as senior vice president responsible for business development at the Biotechnology Innovation Organization (BIO), the world's largest membership organization representing biotechnology companies, academic institutions and state biotechnology centers.
During her 11-year tenure at BIO, Amy played a critical role in expanding the organization’s membership and revenue base and implementing innovative approaches to fundraising, branding, marketing and programming. In 2011 and simultaneous with her BIO responsibilities, she also served as president of the Biotechnology Institute, an organization founded by BIO in 1998 to promote life science education.
Prior to BIO, Amy led corporate communications and investor relations for the former clinical-stage biotechnology company EntreMed Inc. Between 1999 and 2001, she created and implemented the biotech initiative of Montgomery County, Maryland, which included economic development policies, incubator programs, legislative packages and communication plans. Amy began her life sciences career as a government relations director for the National Association of Biomedical Research.
Amy studied at the London School of Economics & Political Science and graduated with a bachelor’s degree in political science from Trinity College in Washington, D.C. A native of Columbus, Ohio, she has lived in the Washington, D.C., metropolitan area for more than 30 years and currently resides in Bethesda, Maryland, with her family.
Wendy Commins Holman
Wendy Commins Holman is the CEO and founder of Ridgeback Biotherapeutics, a biotechnology company focused on developing treatments and diagnostics for underserved patient populations primarily in pediatric orphan and emerging infectious diseases. Ridgeback is partnered with National Institute of Allergy and Infectious Diseases (NIAID)'s Vaccine Research Center to develop mAb114 - a late stage experimental treatment for Ebola Zaire.
Prior to founding Ridgeback in 2015, Ms. Holman was a principal at Ziff Brothers Investments and director of research at ZBI Equities, a multi-billion dollar public equity investment fund. She spent 15 years guiding investments in healthcare and novel technologies, holding various positions during her tenure, including healthcare sector head.
Ms. Holman is a member of the Presidential Advisory Council on HIV/AIDS (PACHA). PACHA provides advice, information and recommendations to the Secretary of Health and Human Services regarding programs, policies and research to promote effective treatment, prevention and cure of HIV disease and AIDS.
Ms. Holman serves on the Penn Libraries Board of Overseers and is the campaign chair for the University of Pennsylvania’s new Biotech Commons. Holman is a trustee for the Ransom Everglades School in Miami, Florida and serves on the Endowment Oversight committee for St. Stephens Episcopal Day School in Coconut Grove, FL.
Ms. Holman earned a bachelor’s of science and economics degree from the University of Pennsylvania’s Wharton School. She lives in Miami, FL with her husband and four children.Return to top
Michael W. Marine, former U.S. Ambassador to the Socialist Republic of Vietnam, served as Chief Executive Officer of the Sabin Vaccine Institute from 2010 to 2016. During his tenure, Ambassador Marine’s leadership was critical to the growth and expansion of the organization and its various programs.
Mr. Marine joined Sabin's leadership team in December 2009 after serving eight months on the Joint Action Committee of the Global Network for Neglected Tropical Diseases, an advocacy and resource mobilization initiative of Sabin.
He was a member of the U.S. State Department’s Foreign Service for 32 years and served as Ambassador to the Socialist Republic of Vietnam from September 2004 to August 2007.
Earlier in his Foreign Service career, Mr. Marine was Deputy Chief of Mission at the U.S. Embassies in Beijing, China, Nairobi, Kenya and Suva, Fiji. He also served in program direction positions in U.S. diplomatic posts in Moscow, Russia, Bonn, Germany and Guangzhou, China.
Mr. Marine enlisted in the U.S. Marine Corps in 1967 and completed his service with the rank of Captain in 1971. He graduated Phi Beta Kappa and summa cum laude from the University of California at Santa Barbara in 1974 with a degree in Asian Studies. He entered the Foreign Service in 1975. He received the State Department’s Superior Honor Award six times.
Governance Committee Chair
Regina Rabinovich is the ExxonMobil Malaria Scholar in Residence at Harvard University and director of the Malaria Elimination Initiative at ISGLOBAL at the University of Barcelona. She currently serves as chair of the Malaria Eradication Scientific Alliance, hosted at ISGLOBAL, and previously led the steering committee for the MalERA Refresh.
She has more than 25 years of experience in global health across research, public health and philanthropic sectors, with a focus on strategy, global health product development and the introduction and scale-up of tools and strategies resulting in impact on endemic populations. Prior to joining Harvard, Dr. Rabinovich served as director of the Infectious Diseases division at the Bill & Melinda Gates Foundation, overseeing the development and implementation of strategies for the prevention, treatment and control of infectious diseases of particular relevance to malaria, pneumonia, diarrhea and neglected infectious diseases. Dr. Rabinovich was chief of the Clinical and Regulatory Affairs Branch at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), focusing on the development and evaluation of vaccines through a network of U.S. clinical research units. She participated in the Children’s Vaccine Initiative, a global effort to prevent infectious diseases in children in the developing world.
In 1999, Dr. Rabinovich became the founding director of the PATH Malaria Vaccine Initiative, a project funded by the Bill & Melinda Gates Foundation to advance efforts to develop promising malaria vaccine candidates. She is past president of the American Society of Tropical Medicine and Hygiene and also serves on the board of the Catholic Medical Mission.
Dr. Rabinovich holds a medical degree from the Southern Illinois University and a master’s degree in public health from the University of North Carolina.
Research & Development Committee Chair
Retired Major General Philip K. Russell, M.D. served in the U.S. Army Medical Corps from 1959 to 1990, pursuing a career in infectious disease and tropical medicine research.
Following his training in internal medicine, he assumed a succession of research assignments at the Walter Reed Army Institute of Research and overseas laboratories in Pakistan, Thailand, and Vietnam. He conducted laboratory and clinical research on a variety of viral and parasitic infectious diseases, including dengue, malaria, hepatitis, and respiratory viruses.
Russell has authored or co-authored more than 150 research publications and contributed to the successful development of several vaccines important to the military and public health, including those of adenovirus, meningitis, and hepatitis A and B. Later, as director of the Walter Reed Army Institute of Research, he led research on vaccines against dengue and malaria. As commander of the U.S. Army Medical Research and Development Command, he spearheaded a major effort to increase the capability of the armed forces to defend against biological agents. His military awards include the legion of Merit and the Distinguished Service Medal.
Following his military service, Russell joined Johns Hopkins University's School of Hygiene and Public Health as professor of international health and worked closely with the World Health Organization as special advisor to the Children's Vaccine Initiative. He was founding board member of the International AIDS Vaccine Initiative. After becoming professor emeritus in 1997, he served as an advisor to the Bill and Melinda Gates Foundation as well as several vaccine programs and was instrumental in creating the Malaria Vaccine Initiative.
Russell has served on numerous advisory boards of national and international agencies, including the Centers for Disease Control, National Institutes of Health and the Institute of Medicine, He served on the Boards of Directors of the International Vaccine Institute and the Aeras Foundation, and continues to be an integral part of the Albert B. Sabin Vaccine Institute. Following the anthrax attacks in 2001, Russell led a Department of Health and Human Services effort to develop and stockpile vaccines and other medical countermeasures against bioterrorism agents. He continues to work on the development of vaccines for the developing world.
Finance & Audit Committee Chair
Peter L. Thoren is executive vice president of Access Industries, a privately held, U.S.-based industrial group with long-term investments worldwide and offices in New York, London and Moscow. Access’s industrial focus spans four key sectors: natural resources and chemicals, media and telecommunications, venture capital and technology, and real estate. Before joining Access in 2001, Mr. Thoren was senior vice president and general counsel of Walker Digital Corporation. Previously, he served in senior management positions with Salomon Inc. and Citigroup, and was an attorney with Rogers & Wells law firm in New York. In addition to corporate boards, Mr. Thoren is on the boards of the New York Academy of Sciences, ThanksUSA and the Darien Historical Society.
A native of Washington, D.C., Mr. Thoren graduated from the University of North Carolina at Chapel Hill (Phi Beta Kappa) and has degrees from the London School of Economics and Political Science and Georgetown University Law Center. He is a member of the New York State Bar and of the Council on Foreign Relations. Mr. Thoren is married and has three grown children.
In Memoriam of Founder and Honorary Trustee
Heloisa Sabin was a founding member of the Sabin Vaccine Institute and served as a trustee or honorary trustee of the Institute from 1993 to 2016. Wife of the late Dr. Albert B. Sabin, Heloisa Sabin dedicated much of her life to continuing the work and legacy of her husband.
An outspoken advocate in the effort to end vaccine preventable diseases, Heloisa shared Dr. Sabin's dedication to the elimination of needless human suffering and poverty. Following her husband's death in 1993, Heloisa joined with Dr. Herman Shepherd, Dr. Robert Chanock and Dr. Philip Russell to found the Sabin Vaccine Institute. She continuously championed the work and legacy of Dr. Sabin by promoting the role of vaccines in eliminating needless deaths from preventable and treatable diseases. Originally from Brazil, Mrs. Sabin lived in Washington, DC, until her death in October of 2016.
In Memoriam of the Founding Chair
Dr. Shepherd was founding chair of the Sabin Vaccine Institute and served on the Board of Trustees from 1993 to 2010. He also served as the Institute's president for eight years. Until 1993 he was chairman and CEO of Armstrong Pharmaceuticals, Inc., which he founded as Aerosol Techniques in 1955.
A world-recognized expert on aerosol technologies, Shepherd spearheaded the development of the metered dose inhaler. He also led a successful effort to fund the nation's first research laboratory dedicated to aerosol pharmaceuticals at Columbia University College of Pharmacy and he is the author of Aerosols: Science and Technology, the first definitive text on the potential of aerosol medications.
Photo by Flickr user francois schnell/CC